Asymmetric cancer cell division regulated by AKT

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 31, 2011, Pages 12845-12850

  Dey Guha, Ipsita ^a,b   Wolfer, Anita ^a,b,f   Yeh, Albert C ^b   Albeck, John G ^b   Darp, Revati ^a   Leon, Eduardo ^a   Wulfkuhle, Julia ^c   Petricoin III, Emanuel F ^c   Wittner, Ben S ^a,b   Ramaswamy, Sridhar ^a,b,d,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GEORGE MASON UNIVERSITY   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e HARVARD STEM CELL INSTITUTE   (United States)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cell signaling; Drug resistance; Epigenetics; Quiescence

Indexed keywords

CYTOKERATIN; MINICHROMOSOME MAINTENANCE PROTEIN 2; PROTEIN KINASE B; TRANSCRIPTION FACTOR HES 1;

ARTICLE; BREAST CANCER; CELL CYCLE G0 PHASE; CELL DIVISION; CELL PROLIFERATION; CELL STRAIN MCF 7; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MITOSIS; PRIORITY JOURNAL; PROGENY; TELOPHASE;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G0 PHASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; LUMINESCENT PROTEINS; MICROSCOPY, CONFOCAL; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 79961218347     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1109632108     Document Type: Article

References (35)

1. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:23-28.
2. Loddo M, et al. (2009) Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer 100:959-970.
3. Massagué J (2004) G1 cell-cycle control and cancer. Nature 432:298-306.
4. Coser KR, et al. (2009) Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc Natl Acad Sci USA 106:14536-14541.
5. Diehn M, et al. (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780-783.
6. Ito K, et al. (2004) Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 431:997-1002. (Pubitemid 39434422)
7. Smith J, Ladi E, Mayer-Proschel M, Noble M (2000) Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. Proc Natl Acad Sci USA 97:10032-10037.
8. Wolfer A, et al. (2010) MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci USA 107:3698-3703.
9. Baxter J, et al. (2004) Histone hypomethylation is an indicator of epigenetic plasticity in quiescent lymphocytes. EMBO J 23:4462-4472. (Pubitemid 39601971)
10. Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693-705.
11. Smith AE, et al. (2009) Epigenetics of human T cells during the G0→G1 transition. Genome Res 19:1325-1337.
12. Barski A, et al. (2009) Chromatin poises miRNA- and protein-coding genes for expression. Genome Res 19:1742-1751.
13. Coller HA, Sang L, Roberts JM (2006) A new description of cellular quiescence. PLoS Biol 4:e83.
14. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988. (Pubitemid 36418143)
15. Mani SA, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715. (Pubitemid 351636299)
16. Paweletz CP, et al. (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20:1981-1989.
17. Zhou J, et al. (2007) Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 104:16158-16163. (Pubitemid 350099378)
18. Manning BD, Cantley LC (2007) AKT/PKB signaling: Navigating downstream. Cell 129:1261-1274. (Pubitemid 46962095)
19. She QB, et al. (2008) Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 3:e3065.
20. Bilodeau MT, et al. (2008) Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorg Med Chem Lett 18:3178-3182. (Pubitemid 351718345)
21. Hirai H, et al. (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9:1956-1967.
22. Winograd-Katz SE, Levitzki A (2006) Cisplatin induces PKB/Akt activation and p38 (MAPK) phosphorylation of the EGF receptor. Oncogene 25:7381-7390. (Pubitemid 44853429)
23. Tothova Z, et al. (2007) FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128:325-339. (Pubitemid 46137992)
24. Nogueira V, et al. (2008) Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14:458-470.
25. Choi J, et al. (2009) Mst1-FoxO signaling protects naïve T lymphocytes from cellular oxidative stress in mice. PLoS One 4:e8011.
26. Mabuchi S, et al. (2002) Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 277:33490-33500. (Pubitemid 34984873)
27. Roesch A, et al. (2010) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141:583-594.
28. Sharma SV, et al. (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141:69-80.
29. Knoblich JA (2010) Asymmetric cell division: Recent developments and their implications for tumour biology. Nat Rev Mol Cell Biol 11:849-860.
30. Morrison SJ, Kimble J (2006) Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 441:1068-1074. (Pubitemid 43990718)
31. Neumüller RA, Knoblich JA (2009) Dividing cellular asymmetry: Asymmetric cell division and its implications for stem cells and cancer. Genes Dev 23:2675-2699.
32. Li L, Clevers H (2010) Coexistence of quiescent and active adult stem cells in mammals. Science 327:542-545.
33. Zhang J, et al. (2006) Bone morphogenetic protein signaling inhibits hair follicle anagen induction by restricting epithelial stem/progenitor cell activation and expansion. Stem Cells 24:2826-2839. (Pubitemid 46053019)
34. Sawyers CL (2006) Will kinase inhibitors have a dark side? N Engl J Med 355:313-315.
35. Sebolt-Leopold JS, English JM (2006) Mechanisms of drug inhibition of signalling molecules. Nature 441:457-462. (Pubitemid 44050141)